Parkman Healthcare Partners LLC Decreases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Parkman Healthcare Partners LLC decreased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 7.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 438,971 shares of the company's stock after selling 35,708 shares during the quarter. Nurix Therapeutics accounts for about 1.3% of Parkman Healthcare Partners LLC's portfolio, making the stock its 27th largest holding. Parkman Healthcare Partners LLC owned approximately 0.62% of Nurix Therapeutics worth $9,864,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Amalgamated Bank raised its holdings in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company's stock valued at $49,000 after acquiring an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company's stock valued at $54,000 after purchasing an additional 559 shares in the last quarter. Quest Partners LLC lifted its position in Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company's stock worth $168,000 after purchasing an additional 1,312 shares during the period. ClariVest Asset Management LLC grew its stake in Nurix Therapeutics by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company's stock worth $1,318,000 after buying an additional 1,766 shares in the last quarter. Finally, Public Employees Retirement System of Ohio raised its position in shares of Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company's stock valued at $747,000 after buying an additional 1,820 shares in the last quarter.

Insider Activity at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 2,368 shares of the company's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the completion of the sale, the chief financial officer now owns 37,270 shares in the company, valued at $905,661. This represents a 5.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Christine Ring sold 5,760 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $22.23, for a total transaction of $128,044.80. Following the completion of the sale, the insider now owns 24,592 shares of the company's stock, valued at approximately $546,680.16. This represents a 18.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,401 shares of company stock valued at $437,453. 9.80% of the stock is owned by corporate insiders.

Nurix Therapeutics Trading Down 0.3 %

NRIX stock traded down $0.07 during mid-day trading on Wednesday, reaching $20.82. The company's stock had a trading volume of 767,625 shares, compared to its average volume of 901,213. Nurix Therapeutics, Inc. has a 12 month low of $7.18 and a 12 month high of $29.56. The business's 50 day moving average price is $23.90 and its 200 day moving average price is $21.92. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -7.18 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on NRIX shares. Oppenheimer boosted their price objective on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a research report on Wednesday, September 4th. UBS Group started coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They set a "buy" rating and a $35.00 price objective for the company. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research report on Friday, October 11th. They issued a "buy" rating and a $41.00 target price on the stock. HC Wainwright increased their target price on shares of Nurix Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Finally, Stephens reaffirmed an "overweight" rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Monday, October 14th. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, Nurix Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.